The roles of regulatory-compliant media and inflammatory/oxytocin priming selection in enhancing human mesenchymal stem/stromal cell immunomodulatory properties Authors: Mahammad Gardashli, Max Baron, Philip Drohat, Daniel Quintero, Lee D Kaplan, Angela Szeto, Armando J Mendez, Thomas M Best, Dimitrios Kouroupis Published: 2024 ABSTRACT AbstractOsteoarthritis (OA) represents a significant global health burden without a known disease modifying agent thereby necessitating pursuit of innovative therapeutic approaches. The infrapatellar fat pad (IFP) serves as a reservoir of mesenchymal stem/stromal cells (MSC), and with adjacent synovium plays key roles in joint disease affecting local inflammatory responses. Therapeutically, IFP-MSC have garnered attention for their potential in OA treatment due to their immunomodulatory and regenerative properties. However, optimizing their therapeutic efficacy necessitates a comprehensive understanding of how growth medium and inflammatory/hormonal priming influence their behavior. In this study, we isolated and expanded IFP-MSC in three different growth media: DMEM + 10% fetal bovine serum (FBS), DMEM + 10% human platelet lysate (HPL), and xeno-/serum-free synthetic (XFSF) medium. Subsequently, cells were induced with an inflammatory/fibrotic cocktail (TIC) with or without oxytocin (OXT). We evaluated various parameters including growth kinetics, phenotype, immunomodulatory capacity, gene expression, and macrophage polarization capacity. Our results revealed significant differences in the behavior of MSC cultured in different media. IFP-MSC cultured in HPL and XFSF exhibited superior growth kinetics and colony-forming abilities compared to those cultured in FBS. Furthermore, both HPL and XFSF media enhanced the expression of MSC markers (> 90%) and potentiated their immunomodulatory properties. Notably, XFSF-conditioned IFP-MSC demonstrated the highest attenuation of peripheral blood mononuclear cell (PBMC) proliferation, indicating their robust immunosuppressive capacity. Additionally, TIC priming further augmented the immunomodulatory functionality of MSC, with IFP-MSC exhibiting enhanced suppression of PBMC proliferation upon TIC priming. Of particular interest, gene expression analysis revealed distinct patterns in TIC + OXT induced MSC compared to TIC only induced, with upregulation of genes associated with immunomodulatory and regenerative functions. Furthermore, TIC + OXT priming promoted M2 polarization in macrophages, suggesting a potential therapeutic strategy for immune-mediated inflammatory joint conditions including OA. Our findings highlight the critical influence of growth medium and inflammatory/hormonal priming on MSC behavior and therapeutic potential. XFSF and HPL media offer promising alternatives to FBS, enhancing MSC growth and immunomodulatory properties. Moreover, TIC + OXT priming represents a novel approach to augment MSC immunomodulation and promote M2 polarization, providing insights into potential therapeutic strategies for OA and other immune-mediated inflammatory conditions.Keywords: Mesenchymal stem/stromal cells, Growth medium, Immunomodulation, Inflammatory priming, Oxytocin priming, Osteoarthritis, Regenerative medicine, Cell therapySubject terms: Stem cells, Mesenchymal stem cells Introduction It is generally agreed that mesenchymal stem/stromal cells (MSC) possess immunomodulatory and trophic effects involving inflammatory, angiogenic, and anti-fibrotic activities1–3. Osteoarthritis (OA), the fourth leading cause of disability worldwide, is a dynamic orchestration of proinflammatory, anti-anabolic, pro-catabolic, and degenerative insults to the articular cartilage as well as other intra-articular and periarticular structures4,5. The current standard of care is designed to improve function and provide pain relief as no disease modifying agents have been identified to date. It has been proposed and tentatively demonstrated that by introducing MSC-based therapies to the treatment regimen for chronic OA that there may be an opportunity to regenerate damaged articular cartilage. At least 10 clinical trials have evaluated the utility of MSC for articular cartilage (AC) regeneration6–12. Although seven of those studies reported improved functional outcomes for patients, findings were inconsistent with regard to histological restoration of healthy AC. One inconsistency between studies reporting histological grades of the AC was the culturing media as well as the mesenchymal cell tissue subtype that were utilized6,8,11. We have previously reported that MSC can modulate local inflammation and fibrosis in synovitis/early OA via paracrine signaling and substance P degradation, making them potential candidates to attenuate the course of chronic musculoskeletal diseases such as OA. Collectively, our studies have demonstrated that the secretome of IFP-MSC can induce a paracrine signaling cascade on local macrophages with a resultant shift to an anti-inflammatory phenotype1,13–15. To date, fetal bovine serum (FBS) MSC supplementation constitutes the most utilized method to produce cell-based products for clinical trials16–18. In fact, up to 80% of clinical trials utilize MSC exposed to animal derivatives. The Federal Drug Administration (FDA) has expressed concerns regarding the variability in animal-derived serum stocks, potential immunologic response, and the possibility of pathogen contamination. Recent proteomic studies have identified 1800 proteins in FBS media that are not consistently quantitatively characterized from batch to batch19–21. On this basis, we have recently reported that compared with FBS-supplemented medium, processing MSC with either human platelet lysate (HPL) or chemically-reinforced/serum-reduced formulation (Ch-R) media similarly enhance their anti-inflammatory, anti-fibrotic, and analgesic properties22,23. The utility of alternative, regulatory-compliant media has attracted scientists and clinicians for years, as this approach minimizes inconsistent reproducibility of results and eliminates immunogenic consequences to the human recipient. Interestingly, the use of HPL carries its own limitations, including batch-to-batch variation, donor-specific immunogenic effects, and variability in donor growth factors24. We have previously demonstrated that culture media differences can modify IFP-MSC phenotypic and functional characteristics22,23,25. To comply with the existing regulatory framework regarding cell-based product manufacturing, eliminate immunogenic activity from source media, and provide confidently reproducible findings, in this study we introduce the use of xeno-free, serum-free medium (XFSF). XFSF is completely synthetic in nature with no components derived from the same or other species, resulting in high reproducibility and low immunogenicity. Herein, to advance the body of evidence supporting the utilization of regulatory-compliant media for treating inflammation and pain in OA and other musculoskeletal disorders, we examined the phenotypic and functional attributes of IFP-MSC expanded in three different media: FBS, HPL, and XFSF-based media. Our primary aim was to investigate IFP-MSC immunomodulatory capacity in each culture medium, both under naïve conditions and in the presence of an inflammatory, pro-fibrotic environment consisting of TNFα, IFNγ, and CTGF (TIC) priming cocktail. Our hypothesis posited that the utilization of XFSF medium would yield comparable, if not superior, results to those obtained with HPL and FBS-based media, particularly in terms of MSC growth kinetics, immunophenotype, immunomodulatory capacity, and functionality in vitro. Our second aim was to study the influence of oxytocin (OXT) on the MSC anti-inflammatory capacity. In recent years, OXT has garnered significant interest for its potential role in priming MSC26–30. OXT, a neuropeptide released from the posterior pituitary, is known to modulate various physiological, behavioral, and anti-inflammatory pathways. Emerging evidence suggests that OXT may also play a role in bone homeostasis and has been linked to the regulation of MSC differentiation, particularly towards osteogenic and chondrogenic lineages31,32. Moreover, OXT has demonstrated efficacy in priming MSC across diverse disease models, including ischemic heart disease33,34. Building upon this body of research highlighting the role of OXT in MSC phenotypic expression, our study sought to investigate the effects of OXT priming on HPL and XFSF-grown IFP-MSC immunomodulatory capacity. Our focus is to investigate how OXT induced MSC may influence the polarization of activated M1 macrophages35. Our previous studies have shown that MSC and their secretome indeed polarize local macrophages from a pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype, known for its immunosuppressive properties13,36–38. By studying the interactions between OXT induced MSC and activated macrophages, our study contributes to a deeper understanding of hormonal modulation in guiding MSC behavior within highly inflammatory environments and disease states. Experimental strategy is described in Fig. 1. Experimental strategy to evaluate phenotypic and functional attributes of IFP-MSC expanded in three different media: FBS, HPL, and XFSF-based media. Results Effects of culture media on IFP-MSC growth kinetics and clonogenic capacity Morphologic differences of IFP-MSC were observed when cultured under the three culture conditions. IFP-MSC expanded in either FBS or XFSF showed a fibroblast-like morphology, while in HPL they had more elongated spindle-shape morphology. All 3 culture conditions demonstrated variable growth kinetics over 8 days. In detail, HPL and XFSF expanded IFP-MSC showed increased growth rate reaching 90% and 98% confluency, respectively, compared to the FBS cultures with only 60% confluency on day 8. XFSF medium showed the most potent growth kinetics compared to the other two culturing conditions entering confluency (> 85%) only 160 h post-seeding in vitro (Fig. 2A). In parallel, TIC priming scheme significantly affected all 3 culture conditions, resulting in reduced growth rates and confluency (< 50%) on day 8. Of note, XFSF medium showed the most decreased growth rate reaching only 10% on day 8 (Fig. 2A). IFP-MSC growth kinetics and clonogenicity. (A) IFP-MSC showed different morphology when expanded in the three different media. Cells expanded in FBS and XFSF had the characteristic fibroblast-like morphology (the latter smaller in size), while HPL were more spindle-shaped. IFP-MSC showed higher growth kinetics in HPL and XFSF compared to FBS conditions. In detail, HPL and XFSF expanded IFP-MSC showed increased growth rate reaching 90% and 98% confluency, respectively, compared to the FBS cultures which had only 60% confluency on day 8. TIC priming negatively affected the growth capacity of IFP-MSC in all three culture conditions. (B) IFP-MSC clonogenic capacity was evident in all three culture conditions. IFP-MSC showed larger CFU-Fs in HPL and XFSF compared to FBS conditions. However, IFP-MSC CFU-F numbers were relatively higher in FBS condition. In detail, HPL and XFSF cultures had lower CFU-F numbers compared to FBS cultures (65 ± 39 for HPL and 76 ± 19 for XFSF vs 168 ± 73 for FBS). All experiments (n = 3 biological donors) were performed independently and data are presented as dot plots and violin plots with mean. Different cultures conditions are presented with distinctive colour tones (HPL: red, XFSF: green, FBS: blue) to allow intra-culture comparisons. Magnification 10X. All 3 culture conditions demonstrated clonogenic capacity but with variable CFU-F sizes and numbers. Specifically, HPL and XFSF cultures showed larger CFU-Fs in size compared to FBS cultures (Fig. 2B). However, HPL and XFSF cultures had lower CFU-F numbers compared to FBS cultures (65 ± 39 for HPL and 76 ± 19 for XFSF vs 168 ± 73 for FBS, Fig. 2B). Effects of culture media on IFP-MSC immunophenotypic profiling Immunophenotypic profiling of IFP-MSC expanded in either HPL or XFSF relative to FBS showed similar high (> 90%) expression levels for all MSC-defining markers (CD105, CD73, CD90, CD44, Fig. 3, upper left panel). In parallel, all three media resulted in pure MSC cultures showing absence of haematopoietic/endothelial cell markers (CD34, CD45, CD56, Fig. 3, bottom left panel). Notably, CD146 and CD10 immune response markers, which are related to potent anti-inflammatory and analgesic MSC actions, showed higher expression levels in XFSF medium (59.7 ± 10.1% and 89.1 ± 5.52%, respectively, Fig. 3 upper right panel) compared to both HPL and FBS media. Interestingly, CD10 showed significantly (p < 0.05) higher expression levels in HPL and XFSF compared to FBS medium. CD283 (TLR3) was enriched especially in the XFSF (90.4 ± 1.85%), whereas CD284 (TLR4) demonstrated low levels of expression in all three cultures. Similarly, we confirmed the absence of HLA-DR in all three cultures. Finally, the platelet activation marker CD142 showed variable levels between the three cultures with higher enrichment in XFSF (50.5 ± 3.96%, Fig. 3 bottom right panel). Immunophenotypic profiling of IFP-MSC. MSC-defining markers (CD105, CD73, CD90, CD44) were highly expressed (> 90%) in all three culture conditions (upper left panel). As expected all MSC cultures showed high purity reflected by the absence of haematopoietic/endothelial markers (CD34, CD45, CD56, bottom left panel). CD146 and CD10, anti-inflammatory and analgesic markers, showed high expression levels specifically in XFSF (59.7 ± 10.1% and 89.1 ± 5.52%, respectively, upper right panel; p < 0.05 compared to IFP-MSC expanded in FBS). CD283 (TLR3) was significantly enriched especially in the XFSF (90.4 ± 1.85%), whereas CD284 (TLR4) demonstrated low levels of expression in all three cultures. Similarly, we confirmed the absence of HLA-DR in all three cultures. Finally, the platelet activation marker CD142 showed variable levels between the three cultures with higher enrichment in XFSF (50.5 ± 3.96%, bottom right panel). All experiments (n = 3 biological donors) were performed independently and data are presented as scatter plots with mean. Different cultures conditions are presented with distinctive colour tones (HPL: red, XFSF: green, FBS: blue) to allow intra-culture comparisons. *p < 0.05. Upon, TIC priming IFP-MSC expanded in either HPL or XFSF relative to FBS showed similar high (> 90%) expression levels for most MSC-defining markers (CD73, CD90, CD44, Fig. 4, upper left panel). Interestingly, CD105 showed high expression (> 90%) in XFSF and FBS but slightly lower expression levels in HPL (85.3 ± 13.5%). Similar to non-induced IFP-MSC all three media showed absence of haematopoietic/endothelial cell markers (CD34, CD45, CD56, Fig. 4, bottom left panel). Exposure to TIC resulted in enhanced expression levels for CD146 anti-inflammatory marker in HPL and XFSF media (56.2 ± 28.8% and 90.7 ± 6.3%, respectively, Fig. 4 upper right panel). Of note, upon exposure to TIC CD10 analgesic marker expression levels were only increased in XFSF and FBS media. CD283 (TLR3) was enriched especially in the HPL (87.9 ± 7.2%), whereas CD284 (TLR4) demonstrated intermediate levels of expression in all three cultures with highest expression levels in HPL (51.9 ± 12.0%). Of interest, TIC priming of XFSF MSC cultures didn’t result in an increase of HLA-DR expression levels whereas HPL and FBS showed variable expression levels (47.9 ± 11.12% and 90.2 ± 4.2%, respectively, Fig. 4 bottom right panel). Finally, the platelet activation marker CD142 showed variable levels between the three cultures with higher enrichment in XFSF (90.7 ± 6.3%, Fig. 4 bottom right panel). Immunophenotypic profiling of IFP-MSC with TIC priming. MSC-defining markers (CD105, CD73, CD90, CD44) were highly expressed in all three culture conditions (upper left panel). Similar to non-induced IFP-MSC, all three TIC induced cultures showed absence of haematopoietic/endothelial cell markers (CD34, CD45, CD56, Fig. 4, bottom left panel). CD146 anti-inflammatory marker showed increased expression in HPL and XFSF media (56.2 ± 28.8% and 90.7 ± 6.3%, respectively, Fig. 4 upper right panel). CD10 analgesic marker expression levels were significantly increased in XFSF compared to HPL and FBS (p < 0.05) media. CD283 (TLR3) was enriched especially in the HPL (87.9 ± 7.2%), whereas CD284 (TLR4) demonstrated intermediate levels of expression in all three cultures with highest expression levels in HPL (51.9 ± 12.0%). Of interest, TIC induced XFSF MSC cultures showed absence of HLA-DR expression levels, whereas HPL and FBS showed variable expression levels (47.9 ± 11.12% and 90.2 ± 4.2%, respectively, Fig. 4 bottom right panel). Finally, the platelet activation marker CD142 showed variable levels between the three cultures with higher enrichment in XFSF (90.7 ± 6.3%, Fig. 4 bottom right panel). All experiments (n = 3 biological donors) were performed independently and data are presented as scatter plots with mean. Different cultures conditions are presented with distinctive colour tones (HPL: red, XFSF: green, FBS: blue) to allow intra-culture comparisons. *p < 0.05, **p < 0.01, ****p < 0.0001. IFP-MSC expanded in either HPL or XFSF show increased capacity to suppress PBMC proliferation in vitro with and without TIC priming CFSE-labeled, PMA/IO-activated human PBMC showed a proliferation of ~ 70%, which was abrogated by co-culture with non-induced or TIC induced IFP-MSC in all three culturing conditions (Fig. 5). Specifically, IFP-MSC expanded in either HPL or XFSF showed increased immunomodulatory capacity in IFP-MSC/PBMC immunopotency co-cultures. TIC priming resulted in increased reduction of activated PBMC proliferation for the three different cultures (in average 4.1% for FBS, 12.1% for HPL, and 57.3% for XFSF). Importantly, only IFP-MSC expanded in XFSF showed a stable and strong suppression of activated PBMC proliferation without and with TIC priming (14.8% and 12.7%, respectively; p < 0.05 compared to IFP-MSC expanded in FBS or HPL). Importantly, the observed PBMC proliferation attenuation upon IFP-MSC co-culture was not due to decreased PBMC viability, as viability remained stable ~ 90% for all tested conditions. PBMC proliferation attenuation by IFP-MSC expanded in three culture conditions with and without TIC priming. IFP-MSC expanded in either HPL or XFSF showed increased immunomodulatory capacity in IFP-MSC/PBMC immunopotency co-cultures. Non-induced IFP-MSC expanded in XFSF showed the highest PMA/IO-stimulated PBMC proliferation attenuation (14.8%). Upon TIC priming, immunomodulatory functionality of IFP-MSC was significantly enhanced especially for HPL and XFSF conditions. Importantly, only IFP-MSC expanded in XFSF showed a stable and strong attenuation of activated PBMC proliferation without and with TIC priming (14.8% and 12.7%, respectively; p < 0.05 compared to IFP-MSC expanded in FBS or HPL). CFSE-labeled, PMA/IO-activated human PBMC monocultures showed a proliferation of ~ 70%, that is represented by grey bars and dotted line. All experiments (n = 3 biological donors) were performed independently and data are presented as bar plots with SD values. *p < 0.05, **p < 0.01. IFP-MSC expanded in either HPL or XFSF show enhanced immunomodulatory and anabolic molecular profile with TIC and OXT priming We confirmed the presence of OXT receptor and OXT mRNA in the IFP-MSC used in the study by qPCR (Supplementary Fig. 1). IFP-MSC expanded in either HPL or XFSF were exposed to TIC and OXT priming (TIC + OXT) for 3 days. Molecular profiling of IFP-MSC exposed to TIC + OXT compared to TIC only priming revealed distinct gene expression profiles for HPL and XFSF (Fig. 6). In XFSF expanded IFP-MSC, 23 out of 85 genes (PROM1, BMP7, IL10, IGF1, GDF7, HNF1A, IFNG, PTPRC, ITGAX, TBX5, GDF5, FZD9, POU5F1, SOX2, ZFP42, PIGS, BMP2, FGF10, VIM, JAG1, WNT3A, TGFB3, PDGFRB) exhibited upregulated expression upon exposure to TIC + OXT (Fig. 6A). All upregulated genes were associated with anabolic and immunomodulatory actions. Reactome analysis of 23 upregulated genes in XFSF TIC + OXT IFP-MSC showed their involvement in six biological processes: cell to cell signaling, positive regulation of signal transduction, positive regulation of cell differentiation, positive regulation of protein phosphorylation, cytokine to cytokine receptor interaction, and positive regulation of cell proliferation. In addition, five signaling pathways were affected by upregulated genes, namely TGF-β, MAPK, Wnt, PI3K Akt, and FGFR pathways. HPL and XFSF expanded IFP-MSC show distinct molecular profile upon exposure to TIC + OXT priming. XFSF (A) and HPL (B) expanded TIC + OXT IFPMSC showed upregulation expression of 23 and 24 out of 85 genes, respectively. All upregulated genes (blue bars) are involved in anabolic and immunomodulatory actions. Reactome analysis of upregulated genes in XFSF or HPL TIC + OXT IFP-MSC showed their involvement in six biological processes and five signaling pathways related to the production of pro-inflammatory cytokines, the recruitment of monocytes, and cartilage homeostasis. Fold expression change of the IFP-MSC genes exposed to TIC + OXT compared to TIC only (dotted line). All experiments (n = 2 biological donors) were performed independently and data are presented as bar plots of mean fold expression change. In HPL expanded IFP-MSC, 24 out of 85 genes (FGF2, FUT1, MCAM, GDF15, ACTA2, BMP6, PROM1, BMP7, GDF7, HNF1A, IFNG, PTPRC, SOX2, EGF, MMP2, BDNF, NGFR, COL1A1, TBX5, RHOA, RUNX2, WNT3A, HDAC1, VWF) exhibited upregulated expression upon exposure to TIC + OXT (Fig. 6B). All upregulated genes were associated with anabolic and immunomodulatory actions. Reactome analysis of 24 upregulated genes in HPL TIC + OXT IFP-MSC showed their involvement in six biological processes: positive regulation of cell proliferation, positive regulation of cell metabolic process, positive regulation of transcription, positive regulation of cell differentiation, positive regulation of response to stimulus, positive regulation of signal transduction. In addition, five signaling pathways were affected by upregulated genes, namely NGF, MAPK, NOTCH, Wnt, and TGF-β pathways. Overall, the distinct genes upregulated in XFSF or HPL TIC + OXT IFP-MSC are involved in the production of pro-inflammatory cytokines, the recruitment of monocytes, and cartilage homeostasis. IFP-MSC expanded in either HPL or XFSF show macrophage polarization capacity with TIC and OXT priming IFP-MSC expanded in either HPL or XFSF were exposed to TIC and OXT priming (TIC + OXT) for 3 days. The co-culture of M1 pro-inflammatory macrophages with TIC + OXT induced IFP-MSC significantly promoted macrophage alternative M2 polarization compared to TIC-only conditions, as evidenced by gene expression analysis (Fig. 7). Specifically, exposure of M1 macrophages to XFSF expanded TIC + OXT induced IFP-MSC resulted in 19-fold upregulation of TLR1 and > 1.5 fold upregulation of IL12A, IL1R2, CD163 genes all related to their M2 polarization. In parallel, M0 transitional phenotype genes, NFKB1 and FABP4, were > threefold upregulated compared to TIC-only. Similarly, exposure of M1 macrophages to HPL expanded TIC + OXT induced IFP-MSC resulted in > 30-fold upregulation of STAT1, TGFB1, and VEGFA genes that are directly related to their M2 polarization. Also, M0 transitional phenotype genes, NFKB1, HLA-DQB1, STAT6, were > threefold upregulated compared to TIC-only. TIC + OXT induced HPL and XFSF expanded IFP-MSC promote M2 macrophages polarization. The co-culture of M1 pro-inflammatory macrophages with TIC + OXT induced IFP-MSC significantly promoted macrophages alternative M2 polarization compared to TIC only conditions, as evidenced by the gene expression analysis. (A) Exposure of M1 macrophages to XFSF expanded TIC + OXT induced IFP-MSC resulted in 19-fold upregulation of TLR1 and > 1.5 fold upregulation of IL12A, IL1R2, CD163 genes all related to their M2 polarization. (B) Exposure of M1 macrophages to HPL expanded TIC + OXT induced IFP-MSC resulted in > 30-fold upregulation of STAT1, TGFB1, and VEGFA genes that are directly related to their M2 polarization. All experiments (n = 2 biological donors) were performed independently and data are presented as bar plots of mean fold expression change. (grey bars: M1, light blue bars: M0, blue bars: M2 polarization, TIC only: dotted line). Overall, upon priming with TIC and OXT both XFSF and HPL expanded IFP-MSC show increased immunomodulatory capacity by polarizing M1 pro-inflammatory macrophages to M2 alternative phenotype. Discussion Reproducible clinical outcomes employing cell-based synovitis/early OA therapeutics depend on reducing the variability of the manufactured cellular products under regulatory-compliant practices. To date, FBS supplementation of MSC constitute the most utilized method to produce cell-based products for clinical trials16–18. However, studies have shown that exposure to FBS significantly increases the risk of viral transmission and immune reaction complications upon transplantation in vivo39. As a potential solution, XFSF media have been developed but their use in MSC culturing still yields variable outcomes in terms of proliferative responses and functionality in vitro40,41. In parallel, HPL media have been used as a viable regulatory-compliant alternative to supplement MSC expansion. Previous studies have shown that HPL contains a series of bioactive molecules which include growth factors, chemokines, and adhesion molecules that can prime MSC to acquire an immunomodulatory phenotype42. Therefore, in the present study we aimed at investigating the therapeutic potential of IFP-MSC in inflammation during synovitis/early OA, contrasting IFP-MSC manufactured with either regulatory-compliant or FBS-containing media, and with and without ex vivo inflammatory and oxytocin priming. In our study, the observed differences in growth kinetics and colony-forming abilities of IFP-MSC under different culture conditions highlight the importance of growth medium selection in MSC expansion protocols. IFP-MSC cultured in HPL and XFSF media exhibited superior growth kinetics and formed larger colonies compared to those cultured in FBS. These results are consistent with previous studies demonstrating the benefits of using HPL or XFSF as supplements for MSC expansion, attributed to their higher proliferation capacity and reduced immunogenicity compared to FBS-supplemented media43,44. A systematic review and meta-analysis determined that both 10% and 5% HPL had a lower doubling time and higher population doubling when compared to the traditional FBS medium43. Similarly, another recent review indicated that XFSF media result in increased growth kinetics and higher cell yields. However, it seems that one type of XFSF medium is not appropriate for all MSC, as different types of MSC showed dissimilar biological characteristics under different XFSF media44. Interestingly, in our study IFP-MSC exposure to TIC priming, which mimics inflammatory and fibrotic microenvironments45,46, negatively affected their growth capacity. This effect may indicate the attenuation of MSC proliferation and their acquisition of a more immunomodulatory functional phenotype upon exposure to inflammatory environment. Furthermore, the high expression levels (> 90%) of MSC-defining markers in HPL and XFSF expanded IFP-MSC, particularly the enrichment of CD146 and CD10 expression, underscore the immunomodulatory properties of MSC in response to regulatory-compliant media. Additionally, in XFSF expanded IFP-MSC, TLR3 was significantly enriched whereas TLR4 showed low levels of expression. These data, in combination with the total absence of HLA-DR expression, show the immunoevasive and anti-inflammatory TLR3-based MSC2 phenotype13 under regulatory-compliant conditions. Specifically, in our previous studies we have demonstrated that CD146 expression is correlated with innately higher MSC immunomodulatory and secretory capacities, and thus therapeutic potency in vivo47. We recently reported that CD10high IFP-MSC after transiently engrafting into areas of joint active synovitis/IFP fibrosis show a potent anti-inflammatory/analgesic phenotype by actively degrading SP via neutral endopeptidase CD101,25. Therefore, XFSF media are inducing the expression of markers that are directly related to superior immunomodulatory properties in vitro and in vivo. These data align with the growing interest in XFSF media as a regulatory-compliant alternative to traditional FBS-supplemented media, offering more consistent and reproducible results while mitigating the risk of immunogenic reactions. Our study delved into the PBMC immunomodulatory capacity of IFP-MSC expanded under different culture environments, both with and without inflammatory conditions (TIC). PBMC immunopotency assay aimed to provide functional assessment of IFP-MSC expanded with different media. Notably, HPL or XFSF expanded IFP-MSC exhibited enhanced immunomodulatory properties, as evidenced by their ability to suppress PBMC proliferation, particularly under XFSF conditions. As expected, TIC priming further augmented the immunomodulatory functionality of IFP-MSC under all three (FBS, HPL, XFSF) culturing conditions. According to our previous studies, TIC induced IFP-MSC demonstrate sustained antagonism of activated PBMC proliferation, significantly outperforming a declining dose-dependent effect with non-induced cells25. However, in the present study only XFSF expanded IFP-MSC showed a stable and strong suppression of activated PBMC proliferation without and with TIC priming. This finding is of outmost importance indicating that XFSF media can functionalize equally to TIC priming IFP-MSC for enhanced PBMC immunosuppression. This preliminary evaluation allowed us to select the best culture conditions (HPL and XFSF) that provide IFP-MSC with strong immunomodulatory capacities for further investigations using a combinatory TIC + OXT priming method. Overall, according to the abovementioned data only HPL and XFSF expanded IFP-MSC show enhanced proliferative capacity, immunophenotypic profile and immunomodulatory properties. On this basis, we proceeded further to assess the effects of two priming schemes (TIC and TIC + OXT) on molecular profile and functionality of specifically HPL and XFSF expanded IFP-MSC. To the best of our knowledge, this is the first time to evaluate the effects of a combinatory inflammatory and hormonal priming on MSC immunomodulatory properties. Our data revealed distinct gene expression profile for TIC + OXT induced IFP-MSC compared to TIC induced. The MSC profile of XFSF expanded TIC + OXT induced IFP-MSC demonstrated an increase in genes associated with MSC stemness, proliferation and inflammatory modulation compared to TIC-alone. Importantly, PROM1 gene that showed the highest expression has been associated with anabolic and anti-inflammatory actions48. From the highly expressed genes both BMP7 and GDF7 are potent growth factors with anabolic properties that belong to the Transforming Growth Factor Beta (TGF-β) superfamily49. Currently, recombinant human BMP7 (rhBMP7) has been utilized in clinical settings to promote the differentiation of MSC neighboring bone fracture sites into chondrocytes and osteoblasts, aid in the formation of new bone through calcium deposition and facilitate the healing process of bone fractures. In terms of bone healing, a recent study investigated BMP7 transfection of MSC on fracture healing. Results showed that BMP7 transfected MSC increased their expression and enhanced differentiation capacity, ultimately promoting fracture healing, suggesting potential for gene therapy in bone regeneration and tissue engineering50. Also, the repair of the tendon-bone interface poses challenges in clinical practice due to its complex composition. On this basis, a recent study investigated the effects of GDF7 on MSC tenogenesis51. In an in vitro tendon regeneration model, GDF-7 not only exhibited tenogenic effects but also stimulated the expression of osteoblastic and adipocytic genes, suggesting its potential as a multifaceted growth factor for tendon-bone interface regeneration51. Other highly expressed genes in XFSF expanded TIC + OXT induced IFP-MSC were IL10 and IGF1, anti-inflammatory signaling molecules that stimulate the growth of chondrocytes, boost the production of ECM, and prevent chondrocyte cell death of PTOA52,53. Specifically, studies showed that IL10 exhibit protective effects on osteoarthritic cartilage, along with anti-inflammatory properties through the decrease of pain mediating signals in the synovium54. Also, recent studies explored the impact of IGF1 on IL-1β-induced apoptosis in rabbit chondrocytes in a rabbit knee OA model. Results demonstrated that IGF1 treatment led to a dose-dependent decrease in MMP expression and apoptotic markers while increasing TIMP-1 levels, indicating chondroprotective effects. Additionally, IGF-1 inhibited ROS production and suppressed the NF-κB pathway by modulating PI3K/Akt and MAPK signaling55. Similarly, MSC profile of HPL expanded TIC + OXT induced IFP-MSC demonstrated increase in genes expression associated with MSC stemness, proliferation and inflammatory modulation compared to TIC-alone. Among these genes are several pivotal ones, including FGF2, FUT1, MCAM, and GDF15. Notably, FGF2 that showed the most pronounced upregulation plays a crucial role in MSC induction towards osteogenic56,57, tenogenic58, and chondrogenic differentiation59, with a favorable influence on osteogenic differentiation evidenced by its capacity to enhance the expression of osteocalcin, a prominent protein in active osteoblasts essential for bone growth56. FGF2 is also a central mediator in angiogenic pathways essential for wound healing60,61. Conversely, FUT1 is recognized for its involvement in ABO self-antigen recognition62 whereas recent studies have unveiled its immunomodulatory properties, particularly its role in inhibiting CD4 T cell proliferation63. Additionally, MCAM (also known as CD146) was found to be upregulated after TIC + OXT priming which has unique implication to MSC functionality relating to immunomodulation and bone regeneration. While CD146 is a well-known marker for stromal and perivascular MSC64–66, our previous data showed that the CD146 signature is correlated with innately higher MSC immunomodulatory and secretory capacities, and thus therapeutic potency in vivo47. It has been also shown to affect signaling pathways involving protein tyrosine kinases FYN and FAK, as well as paxillin67. Activation of FAK and paxillin holds significance in MSC osteogenic differentiation68,69, with high CD146 expression in MSC subpopulations correlating with improved migration and regenerative potential in degenerative intervertebral disc models70. This is supported by Ulrich et. al where CD146 positive MSC significantly increase MSC differentiation towards osteogenesis71. Finally, GDF15 gene expression was also upregulated, known for its role in MSC proliferation, immunomodulation, and osteogenic differentiation. A recent study explored the influence of GDF-15 on MSC secretomes in an Alzheimer’s model, revealing that GDF-15 MSC secreted small extracellular vesicles suppress neuronal apoptosis and neuro-inflammation72. In parallel, others showed that GDF-15 increase MSC mineralization via alkaline phosphatase (ALP) and osteocalcin expression upregulation73. Therefore, overall TIC + OXT priming of both XFSF and HPL expanded MSC resulted in superior immunomodulatory and anabolic molecular profile compared to TIC alone. We also assessed the immunomodulatory capacity of TIC + OXT induced MSC by a macrophage polarization assay. To our knowledge, herein we report for the first time that both XFSF and HPL expanded MSC upon TIC + OXT priming can effectively polarize M1 pro-inflammatory macrophages to the M2 alternative phenotype. Interestingly, M2 phenotype-related genes upregulation has been shown to modulate joint pathogenesis through interactions with resident MSC. We observed significant upregulation of M2 polarization-related genes, TGFB1 and VEGFA (> 30-fold), upon HPL expanded IFP-MSC treatment, and TLR1 gene (19-fold) upon XFSF expanded IFP-MSC treatment. Studies have shown that TGF-β induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype74 whereas VEGF contribute to macrophage recruitment and M2 polarization75. Also, studies showed that IL-10-induced M2 polarized macrophages upregulate among others the expression of TLR1 gene76. However, the most striking finding in our macrophage polarization assay was the dramatic over 60-fold increase in STAT1 expression in the HPL expanded TIC + OXT induced IFP-MSC. STAT1 via STA1-caspase-3 signaling pathway has been implicated in anti-inflammatory pathways in OA77. Specifically, STAT1 mediate the recruitment of inflammatory monocytes and the development of alternatively activated M2 macrophages in vivo78. These data add to the growing body of evidence demonstrating that oxytocin through activation of its receptor can modulate inflammatory responses in a variety of peripheral tissues. For example, in vivo studies have shown that exogenous oxytocin administration can attenuate inflammation in ischemic heart disease79, atherosclerosis80,81, adipose tissue in obesity 82,83, and intestinal inflammation84,85. Such broad efficacy suggests a fundamental role for oxytocin and the oxytocin receptor in modulating inflammatory diseases in a variety of disease states, and the data presented here suggests that oxytocin can additionally modulate the anti-inflammatory capacity of MSC. Ultimately, our data highlight the critical role of IFP-MSC in creating an anti-inflammatory environment within synovial tissue that is conducive to tissue regeneration. The upregulation of genes associated with anabolic and immunomodulatory functions following TIC + OXT priming indicates an enhanced functional capacity in IFP-MSC. These findings carry significant therapeutic implications, suggesting that hormonal priming, such as with oxytocin, could enhance the efficacy of MSC-based treatments for musculoskeletal disorders. Conclusions Collectively, our data suggest that the use of HPL and XFSF regulatory-compliant media for MSC manufacturing in vitro can substantially augment their immunomodulatory therapeutic properties. Functionally, HPL and XFSF media induced IFP-MSC to efficiently suppress PBMC proliferation, and polarize M1 pro-inflammatory macrophages to M2 alternative phenotype. Additionally, we identified distinct immunomodulatory and anabolic gene profiles for the OXT-induced IFP-MSC under inflammatory conditions (TIC). Therefore, our preliminary data suggest that TIC + OXT priming can effectively enhance IFP-MSC immunomodulatory properties in regulatory-compliant conditions. These findings lay the groundwork for enhancing MSC immunomodulatory potency in addressing modulation of immune-mediated inflammatory joint conditions such as OA. Methods Isolation, culture and expansion of IFP-MSC Human IFP-MSC were isolated from IFP tissue acquired from de-identified, non-arthritic patients (n = 6 biological donors, three females and three males, 38 ± 18 years-old) undergoing elective knee arthroscopy at the Lennar Foundation Medical Center at the University of Miami. No organs/tissues were procured from prisoners. All procedures were carried out in accordance with relevant guidelines and regulations by the University of Miami Institutional Review Board. Inform consent and tissue collection approval were waived following “not as human research” indication (based on the nature of the samples as discarded tissue) by the University of Miami Institutional Review Board. IFP tissue (5–10 ml) was mechanically dissected and washed repeatedly with Dulbecco’s Phosphate- Buffered Saline (DPBS; Sigma Aldrich, St Louis, MO, USA), followed by enzymatic digestion with agitation using 235 U/mL collagenase I (Worthington Industries, Columbus, OH, USA) diluted in DPBS and 1% bovine serum albumin (Sigma Aldrich) for 2 h at 37 °C. Enzymatic digestion was inactivated using complete media with Dulbecco’s Modified Eagle’s Medium (DMEM) low-glucose GlutaMAX (Thermo-Fisher Scientific, Waltham, MA, USA) containing 10% FBS (VWR, Radnor, PA, USA), washed and seeded at a density of 1 × 106 cells/175cm2 flask in three different complete media: (i) DMEM + 10% FBS (FBS), (ii) DMEM + 10% HPL (HPL, PL Bioscience, Aachen, Germany) and (iii) xeno-free, serum-free (XFSF, Fujifilm Holdings, Japan, Tokyo). Forty-eight hours post-seeding, non-adherent cells were removed by gently rinsing with DPBS, and media were replenished accordingly. All MSC were cultured at 37 °C 5% (v/v) CO2 until 80% confluent as passage 0 (P0), then passaged at a 1:5 ratio until P3, detaching them with TrypLE select enzyme 1X (Gibco, ThermoFisher Scientific). Experimental strategy is described in Fig. 1. TIC and OXT priming P3 IFP-MSC expanded in all three culturing conditions were subsequently induced with a TIC inflammatory/fibrotic cocktail (15 ng/mL TNFa, 10 ng/mL IFNg, 10 ng/mL connective tissue growth factor, CTGF) with and without 1 nM oxytocin (OXT) for 72 h. The concentrations of priming cytokines and hormone were selected according to our previous dose–response studies 23,25,47. Non-induced and induced samples were evaluated for growth kinetics, immunophenotypic, and functional profiles. Cell proliferation assay To assess their proliferative capability, non-induced and induced IFP-MSC (n = 3) were seeded at a concentration of 1 × 103 cells/well of 24-well plate in triplicates in complete medium. The medium was changed every 3 days and cell proliferative capacity was evaluated as % confluency achieved on day 8 of culture. Growth curves were generated from bright field images obtained using IncuCyte Live Cell Analysis System with IncuCyte ZOOM software (Essen Bioscience, Ann Arbor, MI). Clonogenic assay P3 IFP-MSC expanded in all three culturing conditions (n = 3) were seeded in 100 mm culture plates in triplicates at a density of 103 cells per plate in complete medium. On day 15, colony-forming unit fibroblasts (CFU-Fs) were manually enumerated after cytochemical staining with 0.01% Crystal Violet (Millipore Sigma, Billerica, MA). Immunophenotyping Flow cytometric analysis was performed on P3 IFP-MSC expanded in all three culture conditions (n = 3). 2.0 × 106 cells were stained with Fixable Viability Dye eFluor 780 (Invitrogen) and labelled with antibodies specific for: CD10, CD44, CD73, CD90, CD105, CD56, CD142 (Biolegend, San Diego, CA), CD146, CD45, CD34 (Milteny Biotec, Auburn, CA), HLA-DR (BD Biosciences, San Jose, CA), CD283, CD284 (Invitrogen) and the corresponding isotype controls. Data (20 000 events collected) were acquired using a Cytoflex S (Beckman Coulter, Brea, CA, USA) and analyzed using Kaluza analysis software (Beckman Coulter). Gene expression profiling RNA extraction was performed on TIC + OXT induced IFP-MSC expanded in HPL and XFSF using the RNeasy Mini Kit (Qiagen, Frederick, MD, USA) according to manufacturer’s instructions. Total RNA (1 μg) was used for reverse transcription with SuperScript™ VILO™ cDNA synthesis kit (Invitrogen). A pre-designed 84 gene array (Human Mesenchymal Stem Cell RT2 Profiler PCR array, Qiagen) was performed using 1000 ng cDNA per culture and processed using a StepOne Real-time thermocycler (Applied Biosystems, LLC). Mean values were normalized to ACTB, expression levels were calculated using the 2−ΔΔCt method. Values were represented in a stacked bar plot as the relative fold change of the TIC + OXT induced to TIC induced IFP-MSC alone (reference sample, 2−ΔΔCt = X sample/X reference sample). Putative genes interactomes were generated using a miRNet centric network visual analytics platform (https://www.mirnet.ca/). The data were collected from well-established protein–protein interaction (PPI) database and miRNA-transcription factor-gene interactome network refining was performed with 2.0 betweenness cut-off. Values (with 34 cycles cut-off point) were represented in a topology miRNA-transcription factor-gene interactome network using force atlas layout and hypergeometric test algorithm. Immunopotency assay P3 IFP-MSC were designated as non-induced or TIC induced cohorts expanded in all three culture conditions (n = 3). After 72 h in complete culture (non-induced) or TIC priming (induced) media, IFP-MSC cultures were washed once with DPBS, and media were changed to an immunopotency assay medium containing RPMI (Gibco) with 15% human AB serum (Corning, Corning, NY, USA), 1% L-glutamine (Gibco), 1% non-essential amino acids (Gibco), 1% sodium pyruvate, 1% N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid (Gibco) and 1% 100X vitamins (Gibco). Human peripheral blood mononuclear cells (PBMC, STEMCELL Technologies, Vancouver, Canada) were stained using the CellTrace carboxyfluorescein succinimidyl ester (CFSE) cell proliferation kit (Invitrogen) according to the manufacturer’s instructions and resuspended in immunopotency assay media. Next, CFSE-stained PBMC were added to non-induced or TIC induced IFP-MSC at a 2:1 ratio. The PBMC:IFP-MSC ratio was selected according to our previous dose–response studies25. Cell stimulation cocktail (Invitrogen) containing phorbol 12-myristate 13-acetate and ionomycin was then added at an 1X concentration to the wells designated for PBMC stimulation. After 72 h, CFSE-stained PBMC were collected, stained with Ghost Red 780 Viability Dye (Tonbo Biosciences), and acquisition of 10,000 events was performed using a CytoFLEX S cytometer with CytExpert software (Beckman Coulter). PBMC were gated by scatter, viability and CFSE positivity, and PBMC proliferation was represented as CFSEdim/total CFSE. Macrophage polarization assay Human monocytes (THP-1, ATCC) were differentiated into macrophages using PMA/IO (Phorbol 12-myristate 13-acetate/Ionomycin) at 1X concentration and polarized to M1 macrophages by M1-macrophage generation medium (PromoCell). PMA/IO-stimulated THP-1/IFP-MSC co-cultures were performed for 2 days. Generated macrophage polarization status was assessed using macrophage polarization qPCR array (ScienCell). RNA extraction from THP-1 cultures was performed using the RNeasy Mini Kit (Qiagen, Frederick, MD) according to manufacturer’s instructions. Total RNA (1 μg) was used for reverse transcription with SuperScript™ VILO™ cDNA synthesis kit (Invitrogen). A pre-designed 40 gene Human Macrophage Polarization array (GeneQuery™ Human Macrophage Polarization Markers qPCR Array Kit, ScienCell) was performed using 1000 ng cDNA per culture and processed using StepOne Real-time thermocycler (Applied Biosystems, LLC). Mean values were normalized to GAPDH, expression levels were calculated using the 2−ΔCt method. Values were represented in a stacked bar plot for M0, M1, and M2 polarization as the relative fold change of the PMA/IO + THP-1/IFP-MSC to PMA/IO + THP-1 (reference sample, 2 − ΔCt = X sample/X reference sample). Statistical analysis Normal distribution of values was assessed by the Kolmogorov–Smirnov normality test. In the presence of a non-normal distribution of the data, one-way or two-way ANOVA were used for multiple comparisons. All tests were performed with GraphPad Prism v7.03 (GraphPad Software, San Diego, CA, USA). Statistical significance was considered p < 0.05. Supplementary Information Supplementary Figure 1. Acknowledgements The authors are in gratitude with the Soffer Family Foundation and the DRI Foundation for their generous funding support. These funding sources were not involved in any step of the study design, collection, analysis, or interpretation of the data, or writing of the manuscript. Author contributions M.G, M.B., P.D., D.Q., A.S. Methodology, Software, Validation, Formal analysis, Investigation, Data curation, Writing—original draft, Writing—review & editing, Visualization, and D.K., T.M.B., A.J.M., L.D.K. Conceptualization, Methodology, Software, Validation, Formal analysis, Investigation, Resources, Data curation, Writing—original draft, Writing—review & editing, Visualization, Supervision, Project administration, Funding acquisition. Funding This research was funded by National Institutes of Health, grant number 5R21AR080388-02. Data availability All data generated or analysed during this study are included in this published article [and its supplementary information files]. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Mahammad Gardashli, Max Baron and Philip Drohat contributed equally to this work. Supplementary Information The online version contains supplementary material available at 10.1038/s41598-024-80050-9. References Associated Data Supplementary Materials Supplementary Figure 1. Data Availability Statement All data generated or analysed during this study are included in this published article [and its supplementary information files].